{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T23:49:45Z","timestamp":1767916185362,"version":"3.49.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000200","name":"USAID","doi-asserted-by":"crossref","award":["AID-OAA-A-16-00032"],"award-info":[{"award-number":["AID-OAA-A-16-00032"]}],"id":[{"id":"10.13039\/100000200","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40273-022-01231-w","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T11:02:33Z","timestamp":1678532553000},"page":"787-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Health Economics Research on Non-surgical Biomedical HIV Prevention: Identifying Gaps and Proposing a Way Forward"],"prefix":"10.1007","volume":"41","author":[{"given":"Sergio","family":"Torres-Rueda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1693-5196","authenticated-orcid":false,"given":"Fern","family":"Terris-Prestholt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitzy","family":"Gafos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pitchaya Peach","family":"Indravudh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3028-2742","authenticated-orcid":false,"given":"Rebecca","family":"Giddings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiammetta","family":"Bozzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Quaife","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lusine","family":"Ghazaryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlyn","family":"Mann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Godfrey-Faussett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham","family":"Medley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"key":"1231_CR1","doi-asserted-by":"crossref","unstructured":"Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002(1):CD003255.","DOI":"10.1002\/14651858.CD003255"},{"issue":"7459","key":"1231_CR2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1136\/bmj.329.7459.185","volume":"329","author":"AM Foss","year":"2004","unstructured":"Foss AM, Watts CH, Vickerman P, et al. Condoms and prevention of HIV. BMJ. 2004;329(7459):185\u20136.","journal-title":"BMJ"},{"issue":"8","key":"1231_CR3","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2471\/BLT.11.094268","volume":"90","author":"MD Sweat","year":"2012","unstructured":"Sweat MD, Denison J, Kennedy C, et al. Effects of condom social marketing on condom use in developing countries: a systematic review and meta-analysis, 1990\u20132010. Bull World Health Organ. 2012;90(8):613-622A.","journal-title":"Bull World Health Organ"},{"issue":"21","key":"1231_CR4","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0968-8080(03)02178-5","volume":"11","author":"M Warren","year":"2003","unstructured":"Warren M, Philpott A. Expanding safer sex options: introducing the female condom into national programmes. Reprod Health Matters. 2003;11(21):130\u20139.","journal-title":"Reprod Health Matters"},{"issue":"3","key":"1231_CR5","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1363\/3611404","volume":"36","author":"A Kulczycki","year":"2004","unstructured":"Kulczycki A, Kim DJ, Duerr A, et al. The acceptability of the female and male condom: a randomized crossover trial. Perspect Sex Reprod Health. 2004;36(3):114\u20139.","journal-title":"Perspect Sex Reprod Health"},{"issue":"3","key":"1231_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2307\/3583295","volume":"7","author":"M Francis-Chizororo","year":"2003","unstructured":"Francis-Chizororo M, Natshalaga NR. The female condom: acceptability and perception among rural women in Zimbabwe. Afr J Reprod Health. 2003;7(3):101\u201316.","journal-title":"Afr J Reprod Health"},{"key":"1231_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.17159\/sajs.2018\/20170174","volume":"114","author":"MS Petkova","year":"2018","unstructured":"Petkova MS, Elabor ZB, Djarova-Daniels T, et al. Nurses\u2019 knowledge of and willingness to promote female condom use in Johannesburg Health District. S Afr J Sci. 2018;114:41\u20137.","journal-title":"S Afr J Sci"},{"issue":"5996","key":"1231_CR8","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1126\/science.1193748","volume":"329","author":"Q Abdool Karim","year":"2010","unstructured":"Abdool Karim Q, Abdool Karim S, Frohlich JA, et al. Effectiveness and safety of Tenofovir Gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168\u201374.","journal-title":"Science"},{"issue":"5","key":"1231_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"issue":"27","key":"1231_CR10","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399.","journal-title":"N Engl J Med"},{"issue":"5","key":"1231_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423\u201334.","journal-title":"N Engl J Med"},{"issue":"4","key":"1231_CR12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/s10461-017-2011-3","volume":"22","author":"A Hannaford","year":"2018","unstructured":"Hannaford A, Lipshie-Williams M, Starrels JL, et al. The use of online posts to identify barriers to and facilitators of HIV pre-exposure prophylaxis (PrEP) among men who have sex with men: a comparison to a systematic review of the peer-reviewed literature. AIDS Behav. 2018;22(4):1080\u201395.","journal-title":"AIDS Behav"},{"key":"1231_CR13","unstructured":"AVAC. The future of ARV-based prevention and more (June 2021). 2021. https:\/\/www.avac.org\/infographic\/future-arv-based-prevention. Cited 2021 11 June 2022."},{"key":"1231_CR14","unstructured":"South Africa Health Products Regulatory Authority Approves Dapivirine Ring Developed by the International Partnership for Microbicides. New Brunswick, 2022: Johnson & Johnson."},{"issue":"6 Pt 2","key":"1231_CR15","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1111\/1475-6773.12117","volume":"48","author":"MD Fetters","year":"2013","unstructured":"Fetters MD, Curry LA, Creswell JW. Achieving integration in mixed methods designs-principles and practices. Health Serv Res. 2013;48(6 Pt 2):2134\u201356.","journal-title":"Health Serv Res"},{"key":"1231_CR16","doi-asserted-by":"crossref","unstructured":"Bozzani F, Terris-Prestholt F, Quaife M, et al. Cost and cost-effectiveness of HIV prevention interventions: a systematic literature review. PharmacoEconomics. 2022.","DOI":"10.1007\/s40273-022-01223-w"},{"key":"1231_CR17","doi-asserted-by":"crossref","unstructured":"Giddings R, Indravudh PP, Medley G et al. Infectious disease modelling of HIV prevention interventions: a literature review and narrative synthesis Submitted to PharmacoEconomics, 2022.","DOI":"10.1007\/s40273-023-01260-z"},{"issue":"2","key":"1231_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s40271-020-00486-9","volume":"14","author":"SW Beckham","year":"2021","unstructured":"Beckham SW, Crossnohere NL, Gross M, et al. Eliciting preferences for HIV prevention technologies: a systematic review. Patient. 2021;14(2):151\u201374.","journal-title":"Patient"},{"key":"1231_CR19","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ecolmodel.2014.01.018","volume":"280","author":"V Grimm","year":"2014","unstructured":"Grimm V, Augusiak J, Focks A, et al. Towards better modelling and decision support: documenting model development, testing, and analysis using TRACE. Ecol Model. 2014;280:129\u201339.","journal-title":"Ecol Model"},{"key":"1231_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1049","volume":"346","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMJ. 2013;346: f1049.","journal-title":"BMJ"},{"issue":"10","key":"1231_CR21","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40273-013-0089-7","volume":"31","author":"SM Joy","year":"2013","unstructured":"Joy SM, Little E, Maruthur NM, et al. Patient preferences for the treatment of type 2 diabetes: a scoping review. Pharmacoeconomics. 2013;31(10):877\u201392.","journal-title":"Pharmacoeconomics"},{"key":"1231_CR22","unstructured":"Vassall A, Sweeney S, Kahn JG, et al. Reference case for estimating the costs of global health services and interventions. Global Health Costing Consortium. 2017."},{"key":"1231_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135.","journal-title":"Eur J Epidemiol"},{"key":"1231_CR24","unstructured":"LSHTM HIV Research. Pre-meeting video\u2014stakeholder meeting on biomedical HIV prevention: defining a HE research agenda. 2021. https:\/\/www.youtube.com\/watch?v=0H7WTsuBpi8."},{"issue":"42","key":"1231_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2807\/1560-7917.ES.2017.22.42.17-00192","volume":"22","author":"KJ Ong","year":"2017","unstructured":"Ong KJ, Desai S, Field N, et al. Economic evaluation of HIV pre-exposure prophylaxis among men-who-have-sex-with-men in England in 2016. Euro Surveill. 2017;22(42):17\u201300192.","journal-title":"Euro Surveill"},{"issue":"Suppl 4","key":"1231_CR26","volume":"22","author":"DA Roberts","year":"2019","unstructured":"Roberts DA, Barnabas RV, Abuna F, et al. The role of costing in the introduction and scale-up of HIV pre-exposure prophylaxis: evidence from integrating PrEP into routine maternal and child health and family planning clinics in western Kenya. J Int AIDS Soc. 2019;22(Suppl 4): e25296.","journal-title":"J Int AIDS Soc"},{"issue":"12","key":"1231_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25427","volume":"22","author":"MM van Vliet","year":"2019","unstructured":"van Vliet MM, Hendrickson C, Nichols BE, et al. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study. J Int AIDS Soc. 2019;22(12): e25427.","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"1231_CR28","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1017\/S0950268816002958","volume":"145","author":"G Akudibillah","year":"2017","unstructured":"Akudibillah G, Pandey A, Medlock J. Maximizing the benefits of ART and PrEP in resource-limited settings. Epidemiol Infect. 2017;145(5):942\u201356.","journal-title":"Epidemiol Infect"},{"key":"1231_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1741-7015-12-46","volume":"12","author":"SS Alistar","year":"2014","unstructured":"Alistar SS, Grant PM, Bendavid E. Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South Africa. BMC Med. 2014;12:46.","journal-title":"BMC Med"},{"issue":"11","key":"1231_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013646","volume":"5","author":"C Pretorius","year":"2010","unstructured":"Pretorius C, Stover J, Bollinger L, et al. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS ONE. 2010;5(11): e13646.","journal-title":"PLoS ONE"},{"issue":"4","key":"1231_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175447","volume":"12","author":"RA Alsallaq","year":"2017","unstructured":"Alsallaq RA, Buttolph J, Cleland CM, et al. The potential impact and cost of focusing HIV prevention on young women and men: A modeling analysis in western Kenya. PLoS ONE. 2017;12(4): e0175447.","journal-title":"PLoS ONE"},{"issue":"10","key":"1231_CR32","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s11606-013-2417-1","volume":"28","author":"EF Long","year":"2013","unstructured":"Long EF, Stavert RR. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis. J Gen Intern Med. 2013;28(10):1294\u2013301.","journal-title":"J Gen Intern Med"},{"issue":"10","key":"1231_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186496","volume":"12","author":"G Meyer-Rath","year":"2017","unstructured":"Meyer-Rath G, van Rensburg C, Larson B, et al. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS ONE. 2017;12(10): e0186496.","journal-title":"PLoS ONE"},{"issue":"2","key":"1231_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/QAI.0000000000000145","volume":"66","author":"BE Nichols","year":"2014","unstructured":"Nichols BE, Baltussen R, van Dijk JH, et al. Cost-effectiveness of PrEP in HIV\/AIDS control in Zambia: a stochastic league approach. J Acquir Immune Defic Syndr. 2014;66(2):221\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"1231_CR35","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/S2352-3018(16)30036-4","volume":"3","author":"JA Smith","year":"2016","unstructured":"Smith JA, Anderson SJ, Harris KL, et al. Maximising HIV prevention by balancing the opportunities of today with the promises of tomorrow: a modelling study. Lancet HIV. 2016;3(7):e289\u201396.","journal-title":"Lancet HIV"},{"issue":"2","key":"1231_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/QAI.0000000000002327","volume":"84","author":"M Vogelzang","year":"2020","unstructured":"Vogelzang M, Terris-Prestholt F, Vickerman P, et al. Cost-effectiveness of HIV pre-exposure prophylaxis among heterosexual men in South Africa: a cost-utility modeling analysis. J Acquir Immune Defic Syndr. 2020;84(2):173\u201381.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"Suppl 2","key":"1231_CR37","doi-asserted-by":"publisher","first-page":"S145","DOI":"10.1097\/QAI.0000000000001063","volume":"72","author":"JT Price","year":"2016","unstructured":"Price JT, Wheeler SB, Stranix-Chibanda L, et al. Cost-effectiveness of pre-exposure HIV prophylaxis during pregnancy and breastfeeding in sub-Saharan Africa. J Acquir Immune Defic Syndr. 2016;72(Suppl 2):S145\u201353.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1231_CR38","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12889-020-8334-4","volume":"20","author":"GM Ginsberg","year":"2020","unstructured":"Ginsberg GM, Chemtob D. Cost utility analysis of HIV pre exposure prophylaxis among men who have sex with men in Israel. BMC Public Health. 2020;20(1):271.","journal-title":"BMC Public Health"},{"issue":"6","key":"1231_CR39","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1097\/QAD.0000000000001766","volume":"32","author":"KM Mitchell","year":"2018","unstructured":"Mitchell KM, Dimitrov D, Hughes JP, et al. In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs? AIDS. 2018;32(6):809\u201318.","journal-title":"AIDS"},{"issue":"12","key":"1231_CR40","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1473-3099(16)30311-5","volume":"16","author":"BE Nichols","year":"2016","unstructured":"Nichols BE, Boucher CAB, van der Valk M, et al. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study. Lancet Infect Dis. 2016;16(12):1423\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"1231_CR41","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1080\/09540121.2017.1417528","volume":"30","author":"J Reyes-Urue\u00f1a","year":"2018","unstructured":"Reyes-Urue\u00f1a J, Campbell C, Diez E, et al. Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment. AIDS Care. 2018;30(6):784\u201392.","journal-title":"AIDS Care"},{"issue":"4 Suppl 3","key":"1231_CR42","doi-asserted-by":"publisher","first-page":"19946","DOI":"10.7448\/IAS.18.4.19946","volume":"18","author":"I Cremin","year":"2015","unstructured":"Cremin I, Morales F, Jewell BL, et al. Seasonal PrEP for partners of migrant miners in southern Mozambique: a highly focused PrEP intervention. J Int AIDS Soc. 2015;18(4 Suppl 3):19946.","journal-title":"J Int AIDS Soc"},{"key":"1231_CR43","doi-asserted-by":"crossref","unstructured":"Adamson BJS, Carlson JJ, Kublin JG, et al. The potential cost-effectiveness of pre-exposure prophylaxis combined with HIV vaccines in the United States. Vaccines (Basel). 2017;5(2).","DOI":"10.3390\/vaccines5020013"},{"issue":"8","key":"1231_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25373","volume":"22","author":"B Adamson","year":"2019","unstructured":"Adamson B, Garrison L, Barnabas RV, et al. Competing biomedical HIV prevention strategies: potential cost-effectiveness of HIV vaccines and PrEP in Seattle, WA. J Int AIDS Soc. 2019;22(8): e25373.","journal-title":"J Int AIDS Soc"},{"issue":"36","key":"1231_CR45","doi-asserted-by":"publisher","first-page":"6113","DOI":"10.1016\/j.vaccine.2011.04.013","volume":"29","author":"EF Long","year":"2011","unstructured":"Long EF, Owens DK. The cost-effectiveness of a modestly effective HIV vaccine in the United States. Vaccine. 2011;29(36):6113\u201324.","journal-title":"Vaccine"},{"issue":"1","key":"1231_CR46","doi-asserted-by":"publisher","first-page":"20791","DOI":"10.7448\/IAS.19.1.20791","volume":"19","author":"DR MacFadden","year":"2016","unstructured":"MacFadden DR, Tan DH, Mishra S. Optimizing HIV pre-exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study. J Int AIDS Soc. 2016;19(1):20791.","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"1231_CR47","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s10461-011-0045-5","volume":"16","author":"JJ Kinsler","year":"2012","unstructured":"Kinsler JJ, Cunningham WE, Nure\u00f1a CR, et al. Using conjoint analysis to measure the acceptability of rectal microbicides among men who have sex with men in four South American cities. AIDS Behav. 2012;16(6):1436\u201347.","journal-title":"AIDS Behav"},{"issue":"5","key":"1231_CR48","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1007\/s10461-019-02715-1","volume":"24","author":"EN Browne","year":"2020","unstructured":"Browne EN, Montgomery ET, Mansfield C, et al. Efficacy is not everything: eliciting women\u2019s preferences for a vaginal HIV prevention product using a discrete-choice experiment. AIDS Behav. 2020;24(5):1443\u201351.","journal-title":"AIDS Behav"},{"issue":"3","key":"1231_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1136\/sextrans-2015-052028","volume":"92","author":"EC Tang","year":"2016","unstructured":"Tang EC, Galea JT, Kinsler JJ, et al. Using conjoint analysis to determine the impact of product and user characteristics on acceptability of rectal microbicides for HIV prevention among Peruvian men who have sex with men. Sex Transm Infect. 2016;92(3):200\u20135.","journal-title":"Sex Transm Infect"},{"issue":"5","key":"1231_CR50","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1258\/ijsa.2009.009255","volume":"22","author":"JT Galea","year":"2011","unstructured":"Galea JT, Kinsler JJ, Salazar X, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256\u201362.","journal-title":"Int J STD AIDS"},{"issue":"4","key":"1231_CR51","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1007\/s10461-017-1851-1","volume":"22","author":"R Shrestha","year":"2018","unstructured":"Shrestha R, Karki P, Altice FL, et al. Measuring acceptability and preferences for implementation of pre-exposure prophylaxis (PrEP) using conjoint analysis: an application to primary HIV prevention among high risk drug users. AIDS Behav. 2018;22(4):1228\u201338.","journal-title":"AIDS Behav"},{"issue":"1","key":"1231_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054288","volume":"8","author":"A Wheelock","year":"2013","unstructured":"Wheelock A, Eisingerich AB, Ananworanich J, et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS ONE. 2013;8(1): e54288.","journal-title":"PLoS ONE"},{"issue":"1","key":"1231_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028238","volume":"7","author":"AB Eisingerich","year":"2012","unstructured":"Eisingerich AB, Wheelock A, Gomez GB, et al. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLoS ONE. 2012;7(1): e28238.","journal-title":"PLoS ONE"},{"key":"1231_CR54","doi-asserted-by":"crossref","unstructured":"Parsons JT, Rendina HJ, Whitfield TH, et al. Familiarity with and preferences for oral and long-acting injectable HIV pre-exposure prophylaxis (PrEP) in a National Sample of Gay and bisexual men in the U.S. AIDS Behav. 2016;20(7):1390\u20139.","DOI":"10.1007\/s10461-016-1370-5"},{"issue":"1","key":"1231_CR55","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/0272989X17729376","volume":"38","author":"M Quaife","year":"2018","unstructured":"Quaife M, Eakle R, Cabrera Escobar MA, et al. Divergent preferences for HIV prevention: a discrete choice experiment for multipurpose HIV prevention products in South Africa. Med Decis Mak. 2018;38(1):120\u201333.","journal-title":"Med Decis Mak"},{"issue":"1","key":"1231_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10461-017-1911-6","volume":"22","author":"R Weinrib","year":"2018","unstructured":"Weinrib R, Minnis A, Agot K, et al. End-users\u2019 product preference across three multipurpose prevention technology delivery forms: baseline results from young women in Kenya and South Africa. AIDS Behav. 2018;22(1):133\u201345.","journal-title":"AIDS Behav"},{"issue":"10","key":"1231_CR57","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1007\/s10461-019-02418-7","volume":"23","author":"MO Kuteesa","year":"2019","unstructured":"Kuteesa MO, Quaife M, Biraro S, et al. Acceptability and predictors of uptake of anti-retroviral pre-exposure prophylaxis (PrEP) among fishing communities in Uganda: a cross-sectional discrete choice experiment survey. AIDS Behav. 2019;23(10):2674\u201386.","journal-title":"AIDS Behav"},{"issue":"12","key":"1231_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083193","volume":"8","author":"F Terris-Prestholt","year":"2013","unstructured":"Terris-Prestholt F, Hanson K, MacPhail C, et al. How much demand for New HIV prevention technologies can we really expect? Results from a discrete choice experiment in South Africa. PLoS ONE. 2013;8(12): e83193.","journal-title":"PLoS ONE"},{"issue":"11","key":"1231_CR59","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1007\/s10461-015-1258-9","volume":"20","author":"PA Newman","year":"2016","unstructured":"Newman PA, Cameron MP, Roungprakhon S, et al. Acceptability and preferences for hypothetical rectal microbicides among a community sample of young men who have sex with men and transgender women in Thailand: a discrete choice experiment. AIDS Behav. 2016;20(11):2588\u2013601.","journal-title":"AIDS Behav"},{"issue":"4","key":"1231_CR60","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/QAI.0000000000001945","volume":"80","author":"AM Minnis","year":"2019","unstructured":"Minnis AM, Browne EN, Boeri M, et al. Young women\u2019s stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019;80(4):394\u2013403.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1231_CR61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/0956462418793038","volume":"30","author":"HA Pines","year":"2019","unstructured":"Pines HA, Strathdee SA, Hendrix CW, et al. Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border region. Int J STD AIDS. 2019;30(1):45\u201355.","journal-title":"Int J STD AIDS"},{"issue":"5\u20136","key":"1231_CR62","doi-asserted-by":"publisher","first-page":"791","DOI":"10.17269\/s41997-018-0090-1","volume":"109","author":"J Morgan","year":"2018","unstructured":"Morgan J, Ferlatte O, Salway T, et al. Awareness of, interest in, and willingness to pay for HIV pre-exposure prophylaxis among Canadian gay, bisexual, and other men who have sex with men. Can J Public Health. 2018;109(5\u20136):791\u20139.","journal-title":"Can J Public Health"},{"issue":"3","key":"1231_CR63","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0956462417723817","volume":"29","author":"RI Gilson","year":"2018","unstructured":"Gilson RI, Clutterbuck DJ, Chen ZE. Demand for pre-exposure prophylaxis for HIV and the impact on clinical services: Scottish men who have sex with men perspectives. Int J STD AIDS. 2018;29(3):273\u20137.","journal-title":"Int J STD AIDS"},{"issue":"5","key":"1231_CR64","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1007\/s10461-019-02705-3","volume":"24","author":"KE Lancaster","year":"2020","unstructured":"Lancaster KE, Lungu T, Bula A, et al. Preferences for pre-exposure prophylaxis service delivery among female sex workers in Malawi: a discrete choice experiment. AIDS Behav. 2020;24(5):1294\u2013303.","journal-title":"AIDS Behav"},{"issue":"10","key":"1231_CR65","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/09540120701855375","volume":"20","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Brooks RA, Newman PA, et al. HIV vaccine acceptability among immigrant Thai residents in Los Angeles: a mixed-method approach. AIDS Care. 2008;20(10):1161\u20138.","journal-title":"AIDS Care"},{"issue":"4","key":"1231_CR66","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1258\/ijsa.2011.011189","volume":"23","author":"SJ Lee","year":"2012","unstructured":"Lee SJ, Newman PA, Comulada WS, et al. Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferences. Int J STD AIDS. 2012;23(4):235\u201341.","journal-title":"Int J STD AIDS"},{"issue":"5","key":"1231_CR67","doi-asserted-by":"publisher","first-page":"e413","DOI":"10.17269\/cjph.104.3915","volume":"104","author":"J Weaver","year":"2013","unstructured":"Weaver J, Newman PA, Williams CC, et al. \u201cSisters, Mothers, Daughters and Aunties\u201d: HIV vaccine acceptability among African, Caribbean and other Black women in Toronto. Can J Public Health. 2013;104(5):e413\u20137.","journal-title":"Can J Public Health"},{"issue":"6","key":"1231_CR68","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1111\/j.1475-6773.2009.01039.x","volume":"44","author":"PA Newman","year":"2009","unstructured":"Newman PA, Lee SJ, Duan N, et al. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (LA VOICES). Health Serv Res. 2009;44(6):2167\u201379.","journal-title":"Health Serv Res"},{"issue":"36","key":"1231_CR69","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1016\/j.vaccine.2013.05.089","volume":"31","author":"MP Cameron","year":"2013","unstructured":"Cameron MP, Newman PA, Roungprakhon S, et al. The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine. Vaccine. 2013;31(36):3712\u20137.","journal-title":"Vaccine"},{"issue":"12","key":"1231_CR70","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1016\/j.vaccine.2005.11.013","volume":"24","author":"PA Newman","year":"2006","unstructured":"Newman PA, Duan N, Lee SJ, et al. HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics. Vaccine. 2006;24(12):2094\u2013101.","journal-title":"Vaccine"},{"issue":"4","key":"1231_CR71","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.vaccine.2009.10.142","volume":"28","author":"PA Newman","year":"2010","unstructured":"Newman PA, Roungprakhon S, Tepjan S, et al. Preventive HIV vaccine acceptability and behavioral risk compensation among high-risk men who have sex with men and transgenders in Thailand. Vaccine. 2010;28(4):958\u201364.","journal-title":"Vaccine"},{"issue":"5","key":"1231_CR72","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/j.1524-4733.2007.00312.x","volume":"11","author":"D Whittington","year":"2008","unstructured":"Whittington D, Suraratdecha C, Poulos C, et al. Household demand for preventive HIV\/AIDS vaccines in Thailand: do husbands\u2019 and wives\u2019 preferences differ? Value Health. 2008;11(5):965\u201374.","journal-title":"Value Health"},{"issue":"19\u201320","key":"1231_CR73","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/S0264-410X(02)00152-4","volume":"20","author":"D Whittington","year":"2002","unstructured":"Whittington D, Matsui-Santana O, Freiberger JJ, et al. Private demand for a HIV\/AIDS vaccine: evidence from Guadalajara, Mexico. Vaccine. 2002;20(19\u201320):2585\u201391.","journal-title":"Vaccine"},{"key":"1231_CR74","unstructured":"USAID. USAID announces new award for expanding HIV prevention options for women. 2021."},{"key":"1231_CR75","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/CEOR.S14404","volume":"3","author":"R Goeree","year":"2011","unstructured":"Goeree R, He J, O\u2019Reilly D, et al. Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application. ClinicoEcon Outcomes Res. 2011;3:89\u2013104.","journal-title":"ClinicoEcon Outcomes Res"},{"issue":"1","key":"1231_CR76","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12874-022-01536-6","volume":"22","author":"A Weise","year":"2022","unstructured":"Weise A, B\u00fcchter RB, Pieper D, et al. Assessing transferability in systematic reviews of health economic evaluations\u2014a review of methodological guidance. BMC Med Res Methodol. 2022;22(1):52.","journal-title":"BMC Med Res Methodol"},{"key":"1231_CR77","unstructured":"PEPFAR. The United States President\u2019s emergency plan for AIDS relief: report to congress. 2021."},{"key":"1231_CR78","unstructured":"PEPFAR. PEPFAR 2022 country and regional operation plan (COP\/ROP) guidance for all PEPFAR-supported countries. 2021."},{"issue":"1","key":"1231_CR79","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3390\/pharmaceutics14010048","volume":"14","author":"S Mermelstein","year":"2021","unstructured":"Mermelstein S, Stevens H. TRIPS to where? A narrative review of the empirical literature on intellectual property licensing models to promote global diffusion of essential medicines. Pharmaceutics. 2021;14(1):48.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1231_CR80","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jval.2016.11.009","volume":"20","author":"M Remme","year":"2017","unstructured":"Remme M, Martinez-Alvarez M, Vassal A. Cost-effectiveness thresholds in global health: taking a multisectoral perspective. Value Health. 2017;20(4):699\u2013704.","journal-title":"Value Health"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01231-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-022-01231-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-022-01231-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T17:05:48Z","timestamp":1685552748000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-022-01231-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":80,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1231"],"URL":"https:\/\/doi.org\/10.1007\/s40273-022-01231-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"18 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was carried out with support from USAID cooperative agreement AID-OAA-A-16-00032.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"MQ reports current employment at a healthcare consultancy (Evidera) but does not work in the HIV prevention area in this role. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval for this study was obtained from the Research Ethics Committee of the London School of Hygiene & Tropical Medicine.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients provided consent to participate in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study produced quantitative data from an online survey and qualitative data from a stakeholder meeting. These data are available upon request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"FTP, SM, GM, MG and STR conceived of the study and reviewed the methods. FB, PPI and RG carried out the literature reviews with support from MQ, MG, FTP and STR. STR carried out data collection for the survey and stakeholder meeting. STR, FTP and SM led the analysis, with feedback from all authors. STR drafted the manuscript with support from FTP and SM. All authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}}]}}